Nachrichten | bioMérieux Austria

First-Half 2020 Results

02 September, 2020

Markteinführung des BIOFIRE® MYCOPLASMA-Tests für Mykoplasmen. Nachweis in biopharmazeutischen Produkten

16 Juli, 2020

BIOFIRE® Respiratory Panel 2.1 plus mit SARS-CoV-2 ist CE-markiert

15 Juli, 2020

Second-Quarter 2020 Business Performance Preannouncement

15 Juli, 2020

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS^®

27 Mai, 2020

bioMérieux serology tests for SARS-CoV-2 on VIDAS^® undergo validation preceding imminent launch

06 Mai, 2020

BIOFIRE^® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

04 Mai, 2020

First-Quarter 2020 Business Review

16 April, 2020

bioMérieux receives Emergency Use Authorization for BIOFIRE^® COVID-19 test

24 März, 2020

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

11 März, 2020

Pioneering Diagnostics